We are live on ! Find out more

Lifecore Biomedical

LFCR

Market cap $172M

4.54 USD

-0.11

2.37%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

4.54

0.00

0%

1 day

-2.37%

5 days

-0.87%

1 month

4.61%

3 months

-5.81%

6 months

-36.94%

Year to date

-41.34%

1 year

-39.71%

5 years

-58.23%

10 years

-64.89%

About: Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

Employees: 382

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 87.5%

Negative 0%

Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical Q2 Earnings Call Highlights

Lifecore Biomedical NASDAQ: LFCR reaffirmed its 2026 revenue and adjusted EBITDA guidance while outlining plans to support sharply higher fill-finish demand from its largest customer beginning in 2027.

Lifecore Biomedical Q2 Earnings Call Highlights

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference Call Today at 8:00am ET CHASKA, Minn., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the second quarter and six months ended June 30, 2026.

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Lifecore Biomedical Signs Three New Customer Agreements

--Technology Transfer Agreement for Regenerative Medicine Late-Stage Development Program-- --Two Additional Agreements Supporting Early-Stage Programs Including Formulation and Development for a Global Medical Technology Company -- -- All Programs are Additive to Lifecore's High-Value Pipeline and Expected to Contribute to 2028 Revenue -- CHASKA, Minn., July 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed three new customer agreements, further expanding its pipeline of early- and late-stage programs.

Lifecore Biomedical Signs Three New Customer Agreements

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 3,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore.

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore's Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement with a global pharmaceutical company.

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a manufacturing services agreement with a leading provider of ophthalmic disease management solutions.

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the William Blair 46th Annual Growth Stock Conference.

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

Lifecore Biomedical to Participate at CDMO Live Europe

CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at CDMO Live Europe.

Lifecore Biomedical to Participate at CDMO Live Europe

See News Rankings

Price charts implemented using Lightweight Charts™